Type V hyperlipoproteinemia in systemic lupus erythematosus

Pediatrics International

Volumn 45, Issue 3, 2003, Pages 352-354

  Nakane, Takaya ^a   Asayama, Kohtaro ^b   Higashida, Kosuke ^a   Hayashibe, Hidemasa ^a   Uchida, Norihiko ^a   Dobashi, Kazushige ^b   Kodera, Kohji ^a   Tandou, Tomoko ^a   Furuich, Yoshiyuki ^a   Nakazawa, Shinpei ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Lipoprotein lipase; Systemic lupus erythematosus; Type V hyperlipoproteinemia

Indexed keywords

ANTINUCLEAR ANTIBODY; CARDIOLIPIN ANTIBODY; GENE PRODUCT; HEPARIN; LIPOPROTEIN LIPASE; METHYLPREDNISOLONE; MIZORIBINE; PREDNISOLONE; TRIACYLGLYCEROL;

ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA TYPE 5; IMMUNOPATHOLOGY; IMMUNOREACTIVITY; LABORATORY DIAGNOSIS; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; CHILD; FOLLOW-UP STUDIES; HUMANS; HYPERLIPOPROTEINEMIA TYPE V; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE;

EID: 0043165032     PISSN: 13288067     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-200X.2003.01734.x     Document Type: Article

References (10)

1. Brunzell JD. Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. In: Scriver C, Beaudet AI, Sly WS, Valle D (eds). The Metabolic and Molecular Basis of Inherited Diseases. McGraw-Hill, New York, 1995; 1913-33.
2. Glueck CJ, Levy RI, Glueck HI, Gralnick HR, Greten H, Fredrickson DS. Acquired type I hyperlipoprotinemia with systemic lupus erythematosus, dysglobulinemia and heparine resistance. Am. J. Med. 1969; 47: 318-24.
3. Falko JM, Williams JC, Harvey DG, Weidman SW, Schonfeld G, Dodson WE. Hyperlipoproteinemia and multifocal neurologic dysfunction in systemic lupus erythematosus. J. Pediatr. 1979; 95: 523-9.
4. Paucillo P, De Simone B, Rubba P, Mancini M. A case of association between type I hyperlipoproteinemia and systemic lupus erythematosus (SLE). Effects of steroid treatment. J. Endocrinol. Invest. 1986; 9: 517-20.
5. Stern MP, Kolterman OG, McDevitt H, Reaven GM. Acquired type 3 hyperlipoproteinemia: Report of three cases associated with systemic lupus erythematosus and diabetic ketoacidosis. Arch. Intern. Med. 1972; 130: 817-21.
6. Alverson DC, Chase HP. Systemic lupus erythematosus in childhood presenting as hyperlipoproteinemia. J. Pediatr. 1977; 91: 72-5.
7. Asayama K, Amemiya S, Kusano S, Kato K. Growth-hormone-induced changes in postheparine plasma lipoprotein lipase and hepatic tryglyceride lipase activities. Metabolism 1984; 33: 129-31.
8. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N. Engl. J. Med. 2002; 346: 752-63.
9. Kihara S, Matsuzawa Y, Kubo M et al. Autoimmune hyperchylomicronemia. N. Engl. J. Med. 1989; 320: 1255-9.
10. Borba EF, Bonfá E, Vinagre CGC, Ramires JAF, Maranhão RC. Chylomicron metabolism is markedly altered in systemic lupus erythematosus. Arthritis Rheum. 2000; 43: 1033-40.